Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Centella asiatica extract protects against amyloid β1-40-induced neurotoxicity in neuronal cells by activating the antioxidative defence system.

Chen CL, Tsai WH, Chen CJ, Pan TM.

J Tradit Complement Med. 2015 Aug 1;6(4):362-369. eCollection 2016 Oct.

2.

Plasma β-amyloid in Alzheimer's disease and vascular disease.

Janelidze S, Stomrud E, Palmqvist S, Zetterberg H, van Westen D, Jeromin A, Song L, Hanlon D, Tan Hehir CA, Baker D, Blennow K, Hansson O.

Sci Rep. 2016 May 31;6:26801. doi: 10.1038/srep26801.

3.

Amyloid-associated depression and ApoE4 allele: longitudinal follow-up for the development of Alzheimer's disease.

Qiu WQ, Zhu H, Dean M, Liu Z, Vu L, Fan G, Li H, Mwamburi M, Steffens DC, Au R.

Int J Geriatr Psychiatry. 2016 Mar;31(3):316-22. doi: 10.1002/gps.4339. Epub 2015 Aug 6.

4.

Apolipoprotein E-dependent load of white matter hyperintensities in Alzheimer's disease: a voxel-based lesion mapping study.

Morgen K, Schneider M, Frölich L, Tost H, Plichta MM, Kölsch H, Rakebrandt F, Rienhoff O, Jessen F, Peters O, Jahn H, Luckhaus C, Hüll M, Gertz HJ, Schröder J, Hampel H, Teipel SJ, Pantel J, Heuser I, Wiltfang J, Rüther E, Kornhuber J, Maier W, Meyer-Lindenberg A.

Alzheimers Res Ther. 2015 May 15;7(1):27. doi: 10.1186/s13195-015-0111-8. eCollection 2015.

5.

Blood and CSF biomarkers in brain subcortical ischemic vascular disease: Involved pathways and clinical applicability.

Vilar-Bergua A, Riba-Llena I, Nafría C, Bustamante A, Llombart V, Delgado P, Montaner J.

J Cereb Blood Flow Metab. 2016 Jan;36(1):55-71. Review.

6.

Association between cell-bound blood amyloid-β(1-40) levels and hippocampus volume.

Sotolongo-Grau O, Pesini P, Valero S, Lafuente A, Buendía M, Pérez-Grijalba V, José IS, Ibarria M, Tejero MA, Giménez J, Hernández I, Tárraga L, Ruiz A, Boada M, Sarasa M.

Alzheimers Res Ther. 2014 Oct 20;6(5-8):56. doi: 10.1186/s13195-014-0056-3. eCollection 2014.

7.

Association between amylin and amyloid-β peptides in plasma in the context of apolipoprotein E4 allele.

Qiu WQ, Wallack M, Dean M, Liebson E, Mwamburi M, Zhu H.

PLoS One. 2014 Feb 10;9(2):e88063. doi: 10.1371/journal.pone.0088063. eCollection 2014.

8.

Soluble amyloid-β levels and late-life depression.

Osorio RS, Gumb T, Pomara N.

Curr Pharm Des. 2014;20(15):2547-54.

9.

Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker.

Toledo JB, Shaw LM, Trojanowski JQ.

Alzheimers Res Ther. 2013 Mar 8;5(2):8. doi: 10.1186/alzrt162. eCollection 2013. Review.

10.

Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI.

Toledo JB, Vanderstichele H, Figurski M, Aisen PS, Petersen RC, Weiner MW, Jack CR Jr, Jagust W, Decarli C, Toga AW, Toledo E, Xie SX, Lee VM, Trojanowski JQ, Shaw LM; Alzheimer’s Disease Neuroimaging Initiative.

Acta Neuropathol. 2011 Oct;122(4):401-13. doi: 10.1007/s00401-011-0861-8. Epub 2011 Jul 30.

11.

The relationship between plasma amyloid-β peptides and the medial temporal lobe in the homebound elderly.

Sun X, Bhadelia R, Liebson E, Bergethon P, Folstein M, Zhu JJ, Mwamburi DM, Patz S, Qiu WQ.

Int J Geriatr Psychiatry. 2011 Jun;26(6):593-601. doi: 10.1002/gps.2568. Epub 2010 Dec 9.

12.

Plasma Abeta42 and Abeta40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study.

Seppälä TT, Herukka SK, Hänninen T, Tervo S, Hallikainen M, Soininen H, Pirttilä T.

J Neurol Neurosurg Psychiatry. 2010 Oct;81(10):1123-7. doi: 10.1136/jnnp.2010.205757. Epub 2010 May 16.

13.

Structural neuroimaging in Altheimer's disease: do white matter hyperintensities matter?

Brickman AM, Muraskin J, Zimmerman ME.

Dialogues Clin Neurosci. 2009;11(2):181-90.

14.

Plasma Abeta, homocysteine, and cognition: the Vitamin Intervention for Stroke Prevention (VISP) trial.

Viswanathan A, Raj S, Greenberg SM, Stampfer M, Campbell S, Hyman BT, Irizarry MC.

Neurology. 2009 Jan 20;72(3):268-72. doi: 10.1212/01.wnl.0000339486.63862.db.

15.

Cerebral white matter: neuroanatomy, clinical neurology, and neurobehavioral correlates.

Schmahmann JD, Smith EE, Eichler FS, Filley CM.

Ann N Y Acad Sci. 2008 Oct;1142:266-309. doi: 10.1196/annals.1444.017. Review.

16.

Measuring cerebral atrophy and white matter hyperintensity burden to predict the rate of cognitive decline in Alzheimer disease.

Brickman AM, Honig LS, Scarmeas N, Tatarina O, Sanders L, Albert MS, Brandt J, Blacker D, Stern Y.

Arch Neurol. 2008 Sep;65(9):1202-8. doi: 10.1001/archneur.65.9.1202.

17.

Amyloid-associated depression: a prodromal depression of Alzheimer disease?

Sun X, Steffens DC, Au R, Folstein M, Summergrad P, Yee J, Rosenberg I, Mwamburi DM, Qiu WQ.

Arch Gen Psychiatry. 2008 May;65(5):542-50. doi: 10.1001/archpsyc.65.5.542.

18.

Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study.

Lopez OL, Kuller LH, Mehta PD, Becker JT, Gach HM, Sweet RA, Chang YF, Tracy R, DeKosky ST.

Neurology. 2008 May 6;70(19):1664-71. doi: 10.1212/01.wnl.0000306696.82017.66. Epub 2008 Apr 9.

19.

Neuropathological basis of magnetic resonance images in aging and dementia.

Jagust WJ, Zheng L, Harvey DJ, Mack WJ, Vinters HV, Weiner MW, Ellis WG, Zarow C, Mungas D, Reed BR, Kramer JH, Schuff N, DeCarli C, Chui HC.

Ann Neurol. 2008 Jan;63(1):72-80.

Supplemental Content

Support Center